Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2017 from OUS - Lymphoma biology group

8 publications found

Bollum LK, Huse K, Oksvold MP, Bai B, Hilden VI, Forfang L, Yoon SO, Wälchli S, Smeland EB, Myklebust JH (2017)
BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5
PLoS One, 12 (5), e0177188
DOI 10.1371/journal.pone.0177188, PubMed 28489883

Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S (2017)
Human c-SRC kinase (CSK) overexpression makes T cells dummy
Cancer Immunol Immunother, 67 (4), 525-536
DOI 10.1007/s00262-017-2105-9, PubMed 29248956

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
Oncoimmunology, 6 (4), e1302631
DOI 10.1080/2162402X.2017.1302631, PubMed 28507809

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Clin Cancer Res, 24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C et al. (2017)
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
J Clin Oncol, 35 (15), 1668-1677
DOI 10.1200/JCO.2016.70.7901, PubMed 28291392

Taraldsrud E, Fevang B, Jørgensen SF, Moltu K, Hilden V, Taskén K, Aukrust P, Myklebust JH, Olweus J (2017)
Defective IL-4 signaling in T cells defines severe common variable immunodeficiency
J Autoimmun, 81, 110-119
DOI 10.1016/j.jaut.2017.04.004, PubMed 28476239

Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S (2017)
A TCR-based Chimeric Antigen Receptor
Sci Rep, 7 (1), 10713
DOI 10.1038/s41598-017-11126-y, PubMed 28878363

Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K (2017)
Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations
Cytometry B Clin Cytom, 92 (1), 79-87
DOI 10.1002/cyto.b.21498, PubMed 27933753

 
Page visits: 575011